IRVINE, Calif.--(BUSINESS WIRE)-- Edwards Lifesciences (EW) today announced the company’s SAPIEN M3 mitral valve replacement system is the first transcatheter therapy utilizing a transseptal approach ...
Edwards Lifesciences’ SAPIEN M3 mitral valve replacement system has become the first transcatheter therapy utilizing a transseptal approach to snag FDA approval in the U.S. for the treatment of mitral ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results